Jan Davis
- Hematology top 2%
- Acute Myeloid Leukemia Research 6
- Genetics top 5%
- Hemoglobinopathies and Related Disorders 1
- Chronic Lymphocytic Leukemia Research 1
-
- Histone Deacetylase Inhibitors Research 2
-
- Neutropenia and Cancer Infections 2
- Cancer Treatment and Pharmacology 2
-
- Pneumocystis jirovecii pneumonia detection and treatment 2
-
- Chemotherapy-induced cardiotoxicity and mitigation 1
- Co-authors
- Hagop M. KantarjianGuillermo Garcia‐ManeroSusan O’BrienFrancis J. GilesJörge E. CortesJean‐Pierre J. IssaStefan FaderlWilliam G. Wierda
- Journals
- Blood (5 papers)Journal of Clinical Oncology (1 paper)PubMed (1 paper)
- Partner nations
- United States
In The Last Decade
Jan Davis
7 papers receiving 801 citations
Hit Papers
Peers
Comparison fields: 5 of 51
- Hematology 619
- Genetics 194
- Public Health, Environmental and Occupational Health 229
- Molecular Biology 436
- Oncology 89
Countries citing papers authored by Jan Davis
This map shows the geographic impact of Jan Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Davis more than expected).
Fields of papers citing papers by Jan Davis
This network shows the impact of papers produced by Jan Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Davis. The network helps show where Jan Davis may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jan Davis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiabreakdown → | 2006 | 515 |
| 2 | 2005 | 24 | |
| 3 | 2005 | 8 | |
| 4 | 2005 | 4 | |
| 5 | 2004 | 18 | |
| 6 | 2003 | 242 | |
| 7 | A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. | 2002 | 8 |
About Jan Davis
Jan Davis is a scholar working on Hematology, Genetics and Dermatology, having authored 7 papers that have together received 819 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), Neutropenia and Cancer Infections (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers), Cancer Treatment and Pharmacology (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Hemoglobinopathies and Related Disorders (1 paper), Chemotherapy-induced cardiotoxicity and mitigation (1 paper) and Chronic Lymphocytic Leukemia Research (1 paper). The work is most often cited by research in Hematology (619 citations), Genetics (194 citations) and Public Health, Environmental and Occupational Health (229 citations). Jan Davis has collaborated with scholars based in United States. Frequent co-authors include Hagop M. Kantarjian, Guillermo Garcia‐Manero, Susan O’Brien, Francis J. Giles, Jörge E. Cortes, Jean‐Pierre J. Issa, Stefan Faderl, William G. Wierda, Farhad Ravandi and Alessandra Ferrajoli. Their work appears in journals such as Blood, Journal of Clinical Oncology and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.